文献速递免疫规划

无细胞与全细胞百日咳疫苗免疫后不良事件比较:一项系统综述

Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: A systematic review.
PubMed 文献 · Vaccine · 2018-08-22

该系统综述比较了全细胞百日咳疫苗(wP)与无细胞百日咳疫苗(aP)首剂接种后不良事件(AEFI)的频率。结果显示,wP首剂后AEFI患病率范围为0%至75%,aP为0%至39%;双臂研究风险比显示wP首剂相比aP增加局部反应、注射部位疼痛、肿胀、发热超过38°C及嗜睡的风险,但呕吐风险未达统计学显著。结论确认wP比aP反应原性更强,对wP基础免疫后aP加强的策略应谨慎对待。

要点

  • wP首剂后AEFI患病率0%至75%,aP首剂后为0%至39%。
  • wP首剂相比aP:局部反应RR 2.73(2.33, 3.21),注射部位疼痛RR 4.15(3.24, 5.31)。
  • wP首剂相比aP:肿胀RR 4.38(2.70, 7.12),发热超过38°C RR 9.21(5.39, 15.76),嗜睡RR 1.34(1.18, 1.52)。

核心结论

  • 结果确认,比较首剂时wP比aP反应原性更强,所提出的wP基础免疫后aP加强的百日咳疫苗策略应谨慎对待。

研究设计与样本

  • 系统综述,严格按已发表方案进行,纳入研究包括单臂和双臂研究,单臂研究间存在高异质性,未能合并患病率估计。

主要发现

  • wP首剂AEFI患病率范围为0至75%,aP首剂为0至39%;wP第二剂和第三剂AEFI患病率范围分别为0至71%和0至61%。
  • 双臂研究中,wP首剂相比aP:局部反应RR 2.73(2.33, 3.21),注射部位疼痛RR 4.15(3.24, 5.31),注射部位肿胀RR 4.38(2.70, 7.12),发热超过38°C RR 9.21(5.39, 15.76),嗜睡RR 1.34(1.18, 1.52),呕吐RR 1.28(0.91, 1.79)。

关键数值与推荐

  • wP首剂相比aP的局部反应RR 2.73(2.33, 3.21)。
  • wP首剂相比aP的注射部位疼痛RR 4.15(3.24, 5.31)。
  • wP首剂相比aP的注射部位肿胀RR 4.38(2.70, 7.12)。
  • wP首剂相比aP的发热超过38°C RR 9.21(5.39, 15.76)。
  • wP首剂相比aP的嗜睡RR 1.34(1.18, 1.52),呕吐RR 1.28(0.91, 1.79)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 纳入的单臂研究间存在高异质性,未能合并患病率估计。
  • 所提出的wP基础免疫后aP加强的百日咳疫苗策略应谨慎对待。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Two types of vaccines are currently licensed for use against pertussis: whole-cell (wP) and acellular pertussis (aP). There is evidence that wP confers more durable immunity than aP, however wP has been more frequently associated with adverse events following immunisation (AEFI). A comparison of the frequency of AEFI with the first doses of wP and aP has not yet been clearly documented. This must be done in light of recent considerations to move towards a wP prime-aP boost vaccination strategy in low and middle-income countries. OBJECTIVES: To compare the frequency of AEFI associated with the first dose of the wP and aP vaccines. We also compared the frequency of AEFI associated with subsequent doses of wP. METHODS: This systematic review was carried out in strict accordance with the published protocol. RESULTS: High heterogeneity amongst included one-armed studies did not allow for pooling of prevalence estimates. The prevalence estimates of AEFI at first vaccine dose of wP ranged from 0 to 75%, while the prevalence estimates of AEFI at first vaccine dose of aP ranges from 0 to 39%. The prevalence estimates of adverse events following second and third vaccine dose of wP ranged from 0 to 71% and 0 to 61%, respectively. Risk ratios among two-armed studies showed an increased risk of adverse events with first dose of wP compared to aP [local reaction RR 2.73 (2.33, 3.21), injection site pain RR 4.15 (3.24, 5.31), injection site swelling RR 4.38 (2.70, 7.12), fever over 38 °C RR 9.21 (5.39, 15.76), drowsiness RR 1.34 (1.18, 1.52) and vomiting RR 1.28 (0.91, 1.79)]. CONCLUSION: Our results confirm that, when comparing the first dose, wP is more reacotgenic than aP. The proposed wP prime followed by aP boost pertussis vaccine strategy should be approached with caution.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Patterson J, Kagina BM, Gold M, et al. Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: A systematic review. Vaccine. 2018. PMID: 30143272. doi:10.1016/j.vaccine.2018.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。